By Fineline Cube 
China-based WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi STA (a subsidiary of WuXi AppTec Co., Ltd, SHA: 603259), has entered into a strategic partnership with Mabsoft Therapeutics. The collaboration focuses on accelerating the discovery and development of innovative antibody drug conjugates (ADCs), with a particular emphasis on immune-stimulating antibody conjugates (ISACs). Financial details of the agreement were not disclosed.
Partnership Objectives
The partnership leverages WuXi XDC’s expertise as a Contract Research and Development Manufacturing Organization (CRDMO) to support MABSOFT’s ISAC pipeline. WuXi XDC will provide comprehensive CRDMO services, encompassing drug discovery, process development, and GMP-compliant manufacturing, to advance MABSOFT’s innovative therapeutic candidates.-Fineline Info & Tech